Global Morphine research

Morphine Comprehensive Study by Application (Arthritis, Diarrhea, Pain Relief, Cancer, Others), Forms (Solid, Liquid), Route of Administration (Oral, Parenteral, Intravenous, Others), Distribution Channel (Online, Offline), End User (Hospitals & Clinics, Research Laboratories, Ambulatory Surgical Centers, Others) Players and Region - Global Market Outlook to 2030

Morphine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Morphine
Morphine is a powerful opiate drug derived from the opium poppy plant. It belongs to a class of drugs called opioid analgesics. It's primarily used as a pain reliever for moderate to severe pain, especially when other pain medications are ineffective or not tolerated. It works by binding to opioid receptors in the central nervous system (CNS) and peripheral nervous system (PNS), reducing the perception of pain. The morphine market's growth is driven by the increasing prevalence of chronic pain, its role in palliative care, and its established efficacy and affordability.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market shortly. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Morphine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Mallinckrodt (United Kingdom), Alcaliber S.A. (Spain), Purdue Pharma L.P. (United States), Sanofi (France), Bora Pharmaceuticals (Taiwan), Sun Pharmaceutical Industries Ltd. (India), Fresenius Kabi AG (Germany), Qinghai Lake Pharmaceutical Co.,Ltd. (China), Northeast Pharmaceutical Group Co., Ltd. (China) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Johnson Matthey (United Kingdom), MANUS AKTTEVA BIOPHARMA LLP (India), Mayne Pharma Group Limited (Australia), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Taj Pharmaceuticals Limited (India), Macfarlan Smith Ltd. (United Kingdom) and Verve Health Care Limited (India).

Segmentation Overview
AMA Research has segmented the market of Global Morphine market by , Application (Arthritis, Diarrhea, Pain Relief, Cancer and Others) and Region.



On the basis of geography, the market of Morphine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Forms, the sub-segment i.e. Solid will boost the Morphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Morphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Morphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the Morphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Adoption of Morphine as Painkiller

Market Growth Drivers:
Increasing Prevalence of Pain-Related Conditions and Growing Geriatric Population

Challenges:
Strict Regulations and Rising Scrutiny and Manufacturing Limitation

Restraints:
Side Effects Associated with the Morphine

Opportunities:
Advancements in Drug Delivery Systems, Increase in Healthcare Expenditure and Emerging Markets

Market Leaders and their expansionary development strategies
In January 2024, Bora Pharmaceuticals acquired Upsher-Smith Laboratories. This acquisition marked Bora's first entry into the US market, signifying a significant expansion for the company. It provided Bora with additional manufacturing capacity and a portfolio of 48 generic products, such as morphine, potassium chloride, and testosterone, among many others.
In February 2020, Fresenius Kabi is pleased to announce the launch of Morphine Sulfate injection in a vial format. Fresenius Kabi Morphine is available in two presentations 2 mg/mL and 10 mg/mL per vial. The successful launch of this injection will help Fresenius Kabi to maintain its position as a leader in this competitive market.


Key Target Audience
Morphine Manufacturer, Government Bodies, Suppliers & Distributors, Potential Investors, Research Center and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Arthritis
  • Diarrhea
  • Pain Relief
  • Cancer
  • Others
By Forms
  • Solid
  • Liquid

By Route of Administration
  • Oral
  • Parenteral
  • Intravenous
  • Others

By Distribution Channel
  • Online
  • Offline

By End User
  • Hospitals & Clinics
  • Research Laboratories
  • Ambulatory Surgical Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Pain-Related Conditions
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulations and Rising Scrutiny
      • 3.3.2. Manufacturing Limitation
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Morphine as Painkiller
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Morphine, by Application, Forms, Route of Administration, Distribution Channel, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Morphine (Value)
      • 5.2.1. Global Morphine by: Application (Value)
        • 5.2.1.1. Arthritis
        • 5.2.1.2. Diarrhea
        • 5.2.1.3. Pain Relief
        • 5.2.1.4. Cancer
        • 5.2.1.5. Others
      • 5.2.2. Global Morphine by: Forms (Value)
        • 5.2.2.1. Solid
        • 5.2.2.2. Liquid
      • 5.2.3. Global Morphine by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
        • 5.2.3.3. Intravenous
        • 5.2.3.4. Others
      • 5.2.4. Global Morphine by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
      • 5.2.5. Global Morphine by: End User (Value)
        • 5.2.5.1. Hospitals & Clinics
        • 5.2.5.2. Research Laboratories
        • 5.2.5.3. Ambulatory Surgical Centers
        • 5.2.5.4. Others
      • 5.2.6. Global Morphine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Morphine (Price)
  • 6. Morphine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mallinckrodt (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alcaliber S.A. (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Purdue Pharma L.P. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bora Pharmaceuticals (Taiwan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Kabi AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Qinghai Lake Pharmaceutical Co.,Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Northeast Pharmaceutical Group Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Morphine Sale, by Application, Forms, Route of Administration, Distribution Channel, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Morphine (Value)
      • 7.2.1. Global Morphine by: Application (Value)
        • 7.2.1.1. Arthritis
        • 7.2.1.2. Diarrhea
        • 7.2.1.3. Pain Relief
        • 7.2.1.4. Cancer
        • 7.2.1.5. Others
      • 7.2.2. Global Morphine by: Forms (Value)
        • 7.2.2.1. Solid
        • 7.2.2.2. Liquid
      • 7.2.3. Global Morphine by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
        • 7.2.3.3. Intravenous
        • 7.2.3.4. Others
      • 7.2.4. Global Morphine by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
      • 7.2.5. Global Morphine by: End User (Value)
        • 7.2.5.1. Hospitals & Clinics
        • 7.2.5.2. Research Laboratories
        • 7.2.5.3. Ambulatory Surgical Centers
        • 7.2.5.4. Others
      • 7.2.6. Global Morphine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Morphine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Morphine: by Application(USD Million)
  • Table 2. Morphine Arthritis , by Region USD Million (2018-2023)
  • Table 3. Morphine Diarrhea , by Region USD Million (2018-2023)
  • Table 4. Morphine Pain Relief , by Region USD Million (2018-2023)
  • Table 5. Morphine Cancer , by Region USD Million (2018-2023)
  • Table 6. Morphine Others , by Region USD Million (2018-2023)
  • Table 7. Morphine: by Forms(USD Million)
  • Table 8. Morphine Solid , by Region USD Million (2018-2023)
  • Table 9. Morphine Liquid , by Region USD Million (2018-2023)
  • Table 10. Morphine: by Route of Administration(USD Million)
  • Table 11. Morphine Oral , by Region USD Million (2018-2023)
  • Table 12. Morphine Parenteral , by Region USD Million (2018-2023)
  • Table 13. Morphine Intravenous , by Region USD Million (2018-2023)
  • Table 14. Morphine Others , by Region USD Million (2018-2023)
  • Table 15. Morphine: by Distribution Channel(USD Million)
  • Table 16. Morphine Online , by Region USD Million (2018-2023)
  • Table 17. Morphine Offline , by Region USD Million (2018-2023)
  • Table 18. Morphine: by End User(USD Million)
  • Table 19. Morphine Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 20. Morphine Research Laboratories , by Region USD Million (2018-2023)
  • Table 21. Morphine Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 22. Morphine Others , by Region USD Million (2018-2023)
  • Table 23. South America Morphine, by Country USD Million (2018-2023)
  • Table 24. South America Morphine, by Application USD Million (2018-2023)
  • Table 25. South America Morphine, by Forms USD Million (2018-2023)
  • Table 26. South America Morphine, by Route of Administration USD Million (2018-2023)
  • Table 27. South America Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 28. South America Morphine, by End User USD Million (2018-2023)
  • Table 29. Brazil Morphine, by Application USD Million (2018-2023)
  • Table 30. Brazil Morphine, by Forms USD Million (2018-2023)
  • Table 31. Brazil Morphine, by Route of Administration USD Million (2018-2023)
  • Table 32. Brazil Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 33. Brazil Morphine, by End User USD Million (2018-2023)
  • Table 34. Argentina Morphine, by Application USD Million (2018-2023)
  • Table 35. Argentina Morphine, by Forms USD Million (2018-2023)
  • Table 36. Argentina Morphine, by Route of Administration USD Million (2018-2023)
  • Table 37. Argentina Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 38. Argentina Morphine, by End User USD Million (2018-2023)
  • Table 39. Rest of South America Morphine, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Morphine, by Forms USD Million (2018-2023)
  • Table 41. Rest of South America Morphine, by Route of Administration USD Million (2018-2023)
  • Table 42. Rest of South America Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 43. Rest of South America Morphine, by End User USD Million (2018-2023)
  • Table 44. Asia Pacific Morphine, by Country USD Million (2018-2023)
  • Table 45. Asia Pacific Morphine, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Morphine, by Forms USD Million (2018-2023)
  • Table 47. Asia Pacific Morphine, by Route of Administration USD Million (2018-2023)
  • Table 48. Asia Pacific Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 49. Asia Pacific Morphine, by End User USD Million (2018-2023)
  • Table 50. China Morphine, by Application USD Million (2018-2023)
  • Table 51. China Morphine, by Forms USD Million (2018-2023)
  • Table 52. China Morphine, by Route of Administration USD Million (2018-2023)
  • Table 53. China Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 54. China Morphine, by End User USD Million (2018-2023)
  • Table 55. Japan Morphine, by Application USD Million (2018-2023)
  • Table 56. Japan Morphine, by Forms USD Million (2018-2023)
  • Table 57. Japan Morphine, by Route of Administration USD Million (2018-2023)
  • Table 58. Japan Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 59. Japan Morphine, by End User USD Million (2018-2023)
  • Table 60. India Morphine, by Application USD Million (2018-2023)
  • Table 61. India Morphine, by Forms USD Million (2018-2023)
  • Table 62. India Morphine, by Route of Administration USD Million (2018-2023)
  • Table 63. India Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 64. India Morphine, by End User USD Million (2018-2023)
  • Table 65. South Korea Morphine, by Application USD Million (2018-2023)
  • Table 66. South Korea Morphine, by Forms USD Million (2018-2023)
  • Table 67. South Korea Morphine, by Route of Administration USD Million (2018-2023)
  • Table 68. South Korea Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 69. South Korea Morphine, by End User USD Million (2018-2023)
  • Table 70. Taiwan Morphine, by Application USD Million (2018-2023)
  • Table 71. Taiwan Morphine, by Forms USD Million (2018-2023)
  • Table 72. Taiwan Morphine, by Route of Administration USD Million (2018-2023)
  • Table 73. Taiwan Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 74. Taiwan Morphine, by End User USD Million (2018-2023)
  • Table 75. Australia Morphine, by Application USD Million (2018-2023)
  • Table 76. Australia Morphine, by Forms USD Million (2018-2023)
  • Table 77. Australia Morphine, by Route of Administration USD Million (2018-2023)
  • Table 78. Australia Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 79. Australia Morphine, by End User USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Morphine, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Morphine, by Forms USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Morphine, by Route of Administration USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Morphine, by End User USD Million (2018-2023)
  • Table 85. Europe Morphine, by Country USD Million (2018-2023)
  • Table 86. Europe Morphine, by Application USD Million (2018-2023)
  • Table 87. Europe Morphine, by Forms USD Million (2018-2023)
  • Table 88. Europe Morphine, by Route of Administration USD Million (2018-2023)
  • Table 89. Europe Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 90. Europe Morphine, by End User USD Million (2018-2023)
  • Table 91. Germany Morphine, by Application USD Million (2018-2023)
  • Table 92. Germany Morphine, by Forms USD Million (2018-2023)
  • Table 93. Germany Morphine, by Route of Administration USD Million (2018-2023)
  • Table 94. Germany Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 95. Germany Morphine, by End User USD Million (2018-2023)
  • Table 96. France Morphine, by Application USD Million (2018-2023)
  • Table 97. France Morphine, by Forms USD Million (2018-2023)
  • Table 98. France Morphine, by Route of Administration USD Million (2018-2023)
  • Table 99. France Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 100. France Morphine, by End User USD Million (2018-2023)
  • Table 101. Italy Morphine, by Application USD Million (2018-2023)
  • Table 102. Italy Morphine, by Forms USD Million (2018-2023)
  • Table 103. Italy Morphine, by Route of Administration USD Million (2018-2023)
  • Table 104. Italy Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 105. Italy Morphine, by End User USD Million (2018-2023)
  • Table 106. United Kingdom Morphine, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Morphine, by Forms USD Million (2018-2023)
  • Table 108. United Kingdom Morphine, by Route of Administration USD Million (2018-2023)
  • Table 109. United Kingdom Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 110. United Kingdom Morphine, by End User USD Million (2018-2023)
  • Table 111. Netherlands Morphine, by Application USD Million (2018-2023)
  • Table 112. Netherlands Morphine, by Forms USD Million (2018-2023)
  • Table 113. Netherlands Morphine, by Route of Administration USD Million (2018-2023)
  • Table 114. Netherlands Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 115. Netherlands Morphine, by End User USD Million (2018-2023)
  • Table 116. Rest of Europe Morphine, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Morphine, by Forms USD Million (2018-2023)
  • Table 118. Rest of Europe Morphine, by Route of Administration USD Million (2018-2023)
  • Table 119. Rest of Europe Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 120. Rest of Europe Morphine, by End User USD Million (2018-2023)
  • Table 121. MEA Morphine, by Country USD Million (2018-2023)
  • Table 122. MEA Morphine, by Application USD Million (2018-2023)
  • Table 123. MEA Morphine, by Forms USD Million (2018-2023)
  • Table 124. MEA Morphine, by Route of Administration USD Million (2018-2023)
  • Table 125. MEA Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 126. MEA Morphine, by End User USD Million (2018-2023)
  • Table 127. Middle East Morphine, by Application USD Million (2018-2023)
  • Table 128. Middle East Morphine, by Forms USD Million (2018-2023)
  • Table 129. Middle East Morphine, by Route of Administration USD Million (2018-2023)
  • Table 130. Middle East Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 131. Middle East Morphine, by End User USD Million (2018-2023)
  • Table 132. Africa Morphine, by Application USD Million (2018-2023)
  • Table 133. Africa Morphine, by Forms USD Million (2018-2023)
  • Table 134. Africa Morphine, by Route of Administration USD Million (2018-2023)
  • Table 135. Africa Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 136. Africa Morphine, by End User USD Million (2018-2023)
  • Table 137. North America Morphine, by Country USD Million (2018-2023)
  • Table 138. North America Morphine, by Application USD Million (2018-2023)
  • Table 139. North America Morphine, by Forms USD Million (2018-2023)
  • Table 140. North America Morphine, by Route of Administration USD Million (2018-2023)
  • Table 141. North America Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 142. North America Morphine, by End User USD Million (2018-2023)
  • Table 143. United States Morphine, by Application USD Million (2018-2023)
  • Table 144. United States Morphine, by Forms USD Million (2018-2023)
  • Table 145. United States Morphine, by Route of Administration USD Million (2018-2023)
  • Table 146. United States Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 147. United States Morphine, by End User USD Million (2018-2023)
  • Table 148. Canada Morphine, by Application USD Million (2018-2023)
  • Table 149. Canada Morphine, by Forms USD Million (2018-2023)
  • Table 150. Canada Morphine, by Route of Administration USD Million (2018-2023)
  • Table 151. Canada Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 152. Canada Morphine, by End User USD Million (2018-2023)
  • Table 153. Mexico Morphine, by Application USD Million (2018-2023)
  • Table 154. Mexico Morphine, by Forms USD Million (2018-2023)
  • Table 155. Mexico Morphine, by Route of Administration USD Million (2018-2023)
  • Table 156. Mexico Morphine, by Distribution Channel USD Million (2018-2023)
  • Table 157. Mexico Morphine, by End User USD Million (2018-2023)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Morphine: by Application(USD Million)
  • Table 169. Morphine Arthritis , by Region USD Million (2025-2030)
  • Table 170. Morphine Diarrhea , by Region USD Million (2025-2030)
  • Table 171. Morphine Pain Relief , by Region USD Million (2025-2030)
  • Table 172. Morphine Cancer , by Region USD Million (2025-2030)
  • Table 173. Morphine Others , by Region USD Million (2025-2030)
  • Table 174. Morphine: by Forms(USD Million)
  • Table 175. Morphine Solid , by Region USD Million (2025-2030)
  • Table 176. Morphine Liquid , by Region USD Million (2025-2030)
  • Table 177. Morphine: by Route of Administration(USD Million)
  • Table 178. Morphine Oral , by Region USD Million (2025-2030)
  • Table 179. Morphine Parenteral , by Region USD Million (2025-2030)
  • Table 180. Morphine Intravenous , by Region USD Million (2025-2030)
  • Table 181. Morphine Others , by Region USD Million (2025-2030)
  • Table 182. Morphine: by Distribution Channel(USD Million)
  • Table 183. Morphine Online , by Region USD Million (2025-2030)
  • Table 184. Morphine Offline , by Region USD Million (2025-2030)
  • Table 185. Morphine: by End User(USD Million)
  • Table 186. Morphine Hospitals & Clinics , by Region USD Million (2025-2030)
  • Table 187. Morphine Research Laboratories , by Region USD Million (2025-2030)
  • Table 188. Morphine Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 189. Morphine Others , by Region USD Million (2025-2030)
  • Table 190. South America Morphine, by Country USD Million (2025-2030)
  • Table 191. South America Morphine, by Application USD Million (2025-2030)
  • Table 192. South America Morphine, by Forms USD Million (2025-2030)
  • Table 193. South America Morphine, by Route of Administration USD Million (2025-2030)
  • Table 194. South America Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 195. South America Morphine, by End User USD Million (2025-2030)
  • Table 196. Brazil Morphine, by Application USD Million (2025-2030)
  • Table 197. Brazil Morphine, by Forms USD Million (2025-2030)
  • Table 198. Brazil Morphine, by Route of Administration USD Million (2025-2030)
  • Table 199. Brazil Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 200. Brazil Morphine, by End User USD Million (2025-2030)
  • Table 201. Argentina Morphine, by Application USD Million (2025-2030)
  • Table 202. Argentina Morphine, by Forms USD Million (2025-2030)
  • Table 203. Argentina Morphine, by Route of Administration USD Million (2025-2030)
  • Table 204. Argentina Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 205. Argentina Morphine, by End User USD Million (2025-2030)
  • Table 206. Rest of South America Morphine, by Application USD Million (2025-2030)
  • Table 207. Rest of South America Morphine, by Forms USD Million (2025-2030)
  • Table 208. Rest of South America Morphine, by Route of Administration USD Million (2025-2030)
  • Table 209. Rest of South America Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 210. Rest of South America Morphine, by End User USD Million (2025-2030)
  • Table 211. Asia Pacific Morphine, by Country USD Million (2025-2030)
  • Table 212. Asia Pacific Morphine, by Application USD Million (2025-2030)
  • Table 213. Asia Pacific Morphine, by Forms USD Million (2025-2030)
  • Table 214. Asia Pacific Morphine, by Route of Administration USD Million (2025-2030)
  • Table 215. Asia Pacific Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 216. Asia Pacific Morphine, by End User USD Million (2025-2030)
  • Table 217. China Morphine, by Application USD Million (2025-2030)
  • Table 218. China Morphine, by Forms USD Million (2025-2030)
  • Table 219. China Morphine, by Route of Administration USD Million (2025-2030)
  • Table 220. China Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 221. China Morphine, by End User USD Million (2025-2030)
  • Table 222. Japan Morphine, by Application USD Million (2025-2030)
  • Table 223. Japan Morphine, by Forms USD Million (2025-2030)
  • Table 224. Japan Morphine, by Route of Administration USD Million (2025-2030)
  • Table 225. Japan Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 226. Japan Morphine, by End User USD Million (2025-2030)
  • Table 227. India Morphine, by Application USD Million (2025-2030)
  • Table 228. India Morphine, by Forms USD Million (2025-2030)
  • Table 229. India Morphine, by Route of Administration USD Million (2025-2030)
  • Table 230. India Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 231. India Morphine, by End User USD Million (2025-2030)
  • Table 232. South Korea Morphine, by Application USD Million (2025-2030)
  • Table 233. South Korea Morphine, by Forms USD Million (2025-2030)
  • Table 234. South Korea Morphine, by Route of Administration USD Million (2025-2030)
  • Table 235. South Korea Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 236. South Korea Morphine, by End User USD Million (2025-2030)
  • Table 237. Taiwan Morphine, by Application USD Million (2025-2030)
  • Table 238. Taiwan Morphine, by Forms USD Million (2025-2030)
  • Table 239. Taiwan Morphine, by Route of Administration USD Million (2025-2030)
  • Table 240. Taiwan Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 241. Taiwan Morphine, by End User USD Million (2025-2030)
  • Table 242. Australia Morphine, by Application USD Million (2025-2030)
  • Table 243. Australia Morphine, by Forms USD Million (2025-2030)
  • Table 244. Australia Morphine, by Route of Administration USD Million (2025-2030)
  • Table 245. Australia Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 246. Australia Morphine, by End User USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Morphine, by Application USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Morphine, by Forms USD Million (2025-2030)
  • Table 249. Rest of Asia-Pacific Morphine, by Route of Administration USD Million (2025-2030)
  • Table 250. Rest of Asia-Pacific Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Morphine, by End User USD Million (2025-2030)
  • Table 252. Europe Morphine, by Country USD Million (2025-2030)
  • Table 253. Europe Morphine, by Application USD Million (2025-2030)
  • Table 254. Europe Morphine, by Forms USD Million (2025-2030)
  • Table 255. Europe Morphine, by Route of Administration USD Million (2025-2030)
  • Table 256. Europe Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 257. Europe Morphine, by End User USD Million (2025-2030)
  • Table 258. Germany Morphine, by Application USD Million (2025-2030)
  • Table 259. Germany Morphine, by Forms USD Million (2025-2030)
  • Table 260. Germany Morphine, by Route of Administration USD Million (2025-2030)
  • Table 261. Germany Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 262. Germany Morphine, by End User USD Million (2025-2030)
  • Table 263. France Morphine, by Application USD Million (2025-2030)
  • Table 264. France Morphine, by Forms USD Million (2025-2030)
  • Table 265. France Morphine, by Route of Administration USD Million (2025-2030)
  • Table 266. France Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 267. France Morphine, by End User USD Million (2025-2030)
  • Table 268. Italy Morphine, by Application USD Million (2025-2030)
  • Table 269. Italy Morphine, by Forms USD Million (2025-2030)
  • Table 270. Italy Morphine, by Route of Administration USD Million (2025-2030)
  • Table 271. Italy Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 272. Italy Morphine, by End User USD Million (2025-2030)
  • Table 273. United Kingdom Morphine, by Application USD Million (2025-2030)
  • Table 274. United Kingdom Morphine, by Forms USD Million (2025-2030)
  • Table 275. United Kingdom Morphine, by Route of Administration USD Million (2025-2030)
  • Table 276. United Kingdom Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 277. United Kingdom Morphine, by End User USD Million (2025-2030)
  • Table 278. Netherlands Morphine, by Application USD Million (2025-2030)
  • Table 279. Netherlands Morphine, by Forms USD Million (2025-2030)
  • Table 280. Netherlands Morphine, by Route of Administration USD Million (2025-2030)
  • Table 281. Netherlands Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 282. Netherlands Morphine, by End User USD Million (2025-2030)
  • Table 283. Rest of Europe Morphine, by Application USD Million (2025-2030)
  • Table 284. Rest of Europe Morphine, by Forms USD Million (2025-2030)
  • Table 285. Rest of Europe Morphine, by Route of Administration USD Million (2025-2030)
  • Table 286. Rest of Europe Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 287. Rest of Europe Morphine, by End User USD Million (2025-2030)
  • Table 288. MEA Morphine, by Country USD Million (2025-2030)
  • Table 289. MEA Morphine, by Application USD Million (2025-2030)
  • Table 290. MEA Morphine, by Forms USD Million (2025-2030)
  • Table 291. MEA Morphine, by Route of Administration USD Million (2025-2030)
  • Table 292. MEA Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 293. MEA Morphine, by End User USD Million (2025-2030)
  • Table 294. Middle East Morphine, by Application USD Million (2025-2030)
  • Table 295. Middle East Morphine, by Forms USD Million (2025-2030)
  • Table 296. Middle East Morphine, by Route of Administration USD Million (2025-2030)
  • Table 297. Middle East Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 298. Middle East Morphine, by End User USD Million (2025-2030)
  • Table 299. Africa Morphine, by Application USD Million (2025-2030)
  • Table 300. Africa Morphine, by Forms USD Million (2025-2030)
  • Table 301. Africa Morphine, by Route of Administration USD Million (2025-2030)
  • Table 302. Africa Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 303. Africa Morphine, by End User USD Million (2025-2030)
  • Table 304. North America Morphine, by Country USD Million (2025-2030)
  • Table 305. North America Morphine, by Application USD Million (2025-2030)
  • Table 306. North America Morphine, by Forms USD Million (2025-2030)
  • Table 307. North America Morphine, by Route of Administration USD Million (2025-2030)
  • Table 308. North America Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 309. North America Morphine, by End User USD Million (2025-2030)
  • Table 310. United States Morphine, by Application USD Million (2025-2030)
  • Table 311. United States Morphine, by Forms USD Million (2025-2030)
  • Table 312. United States Morphine, by Route of Administration USD Million (2025-2030)
  • Table 313. United States Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 314. United States Morphine, by End User USD Million (2025-2030)
  • Table 315. Canada Morphine, by Application USD Million (2025-2030)
  • Table 316. Canada Morphine, by Forms USD Million (2025-2030)
  • Table 317. Canada Morphine, by Route of Administration USD Million (2025-2030)
  • Table 318. Canada Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 319. Canada Morphine, by End User USD Million (2025-2030)
  • Table 320. Mexico Morphine, by Application USD Million (2025-2030)
  • Table 321. Mexico Morphine, by Forms USD Million (2025-2030)
  • Table 322. Mexico Morphine, by Route of Administration USD Million (2025-2030)
  • Table 323. Mexico Morphine, by Distribution Channel USD Million (2025-2030)
  • Table 324. Mexico Morphine, by End User USD Million (2025-2030)
  • Table 325. Research Programs/Design for This Report
  • Table 326. Key Data Information from Secondary Sources
  • Table 327. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Morphine: by Application USD Million (2018-2023)
  • Figure 5. Global Morphine: by Forms USD Million (2018-2023)
  • Figure 6. Global Morphine: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Morphine: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Morphine: by End User USD Million (2018-2023)
  • Figure 9. South America Morphine Share (%), by Country
  • Figure 10. Asia Pacific Morphine Share (%), by Country
  • Figure 11. Europe Morphine Share (%), by Country
  • Figure 12. MEA Morphine Share (%), by Country
  • Figure 13. North America Morphine Share (%), by Country
  • Figure 14. Global Morphine share by Players 2023 (%)
  • Figure 15. Global Morphine share by Players (Top 3) 2023(%)
  • Figure 16. Global Morphine share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Mallinckrodt (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Mallinckrodt (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Alcaliber S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 21. Alcaliber S.A. (Spain) Revenue: by Geography 2023
  • Figure 22. Purdue Pharma L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Purdue Pharma L.P. (United States) Revenue: by Geography 2023
  • Figure 24. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi (France) Revenue: by Geography 2023
  • Figure 26. Bora Pharmaceuticals (Taiwan) Revenue, Net Income and Gross profit
  • Figure 27. Bora Pharmaceuticals (Taiwan) Revenue: by Geography 2023
  • Figure 28. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 29. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 30. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Fresenius Kabi AG (Germany) Revenue: by Geography 2023
  • Figure 32. Qinghai Lake Pharmaceutical Co.,Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 33. Qinghai Lake Pharmaceutical Co.,Ltd. (China) Revenue: by Geography 2023
  • Figure 34. Northeast Pharmaceutical Group Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 35. Northeast Pharmaceutical Group Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Global Morphine: by Application USD Million (2025-2030)
  • Figure 39. Global Morphine: by Forms USD Million (2025-2030)
  • Figure 40. Global Morphine: by Route of Administration USD Million (2025-2030)
  • Figure 41. Global Morphine: by Distribution Channel USD Million (2025-2030)
  • Figure 42. Global Morphine: by End User USD Million (2025-2030)
  • Figure 43. South America Morphine Share (%), by Country
  • Figure 44. Asia Pacific Morphine Share (%), by Country
  • Figure 45. Europe Morphine Share (%), by Country
  • Figure 46. MEA Morphine Share (%), by Country
  • Figure 47. North America Morphine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Mallinckrodt (United Kingdom)
  • Alcaliber S.A. (Spain)
  • Purdue Pharma L.P. (United States)
  • Sanofi (France)
  • Bora Pharmaceuticals (Taiwan)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Fresenius Kabi AG (Germany)
  • Qinghai Lake Pharmaceutical Co.,Ltd. (China)
  • Northeast Pharmaceutical Group Co., Ltd. (China)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Johnson Matthey (United Kingdom) , MANUS AKTTEVA BIOPHARMA LLP (India) , Mayne Pharma Group Limited (Australia) , DAIICHI SANKYO COMPANY, LIMITED. (Japan) , Taj Pharmaceuticals Limited (India) , Macfarlan Smith Ltd. (United Kingdom) , Verve Health Care Limited (India)
Select User Access Type

Key Highlights of Report


Feb 2024 201 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Morphine research Quantitative research analysis
Global Morphine research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Mallinckrodt (United Kingdom), Alcaliber S.A. (Spain), Purdue Pharma L.P. (United States), Sanofi (France), Bora Pharmaceuticals (Taiwan), Sun Pharmaceutical Industries Ltd. (India), Fresenius Kabi AG (Germany), Qinghai Lake Pharmaceutical Co.,Ltd. (China), Northeast Pharmaceutical Group Co., Ltd. (China) and Pfizer Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Adoption of Morphine as Painkiller" is seen as one of major influencing trends for Morphine Market during projected period 2023-2030.
The Morphine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Morphine research Report?

Have a Query? Click Here

Other Related Reports

Allergy Diagnostic Comprehensive Study by Type (Drug Allergens, Inhaled Allergens, Food Allergens, Others), Medications (Antihistamines, Decongestants, Corticosteroids, Others), End-User (Academic R...
$ 3450
Injectable Drug Delivery Comprehensive Study by Type (Devices, Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable ...
$ 3750
Anthrax Vaccines Comprehensive Study by Type (Live Vaccines, Cell free PA Vaccines), Application (Human Use, Animal Use), Disease Type (Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax...
$ 3450
Fibrin Glue Comprehensive Study by Type (Hemostat, Adhesive, Sealant), Application (Hemostasis, Sealing, Tissue Gluing, Support for Wound Healing, Arein cardiac surgery, Burn to bleed, Pulmonary su...
$ 3450
Lignocaine Comprehensive Study by Application (Local Anesthesia, Dentistry, Cardiac Arrhythmia, Epilepsy, Cosmetics, Anti-Arrhythmic, Others), Formulations (Injections, Creams, Ointments, Gels, Aeros...
$ 3450
Pediatric Medicines Comprehensive Study by Application (Hospital, Clinic), Forms (Capsule, Liquid, Ointment, Powder), Diseases (Anemia, Chickenpox, Fever, Asthma, Others), Distribution Channel (Onli...
$ 3800